Pharmesis International Ltd
SGX:BFK
Balance Sheet
Balance Sheet Decomposition
Pharmesis International Ltd
Pharmesis International Ltd
Balance Sheet
Pharmesis International Ltd
| Dec-2004 | Dec-2005 | Dec-2006 | Dec-2007 | Dec-2008 | Dec-2009 | Dec-2010 | Dec-2011 | Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||||
| Cash & Cash Equivalents |
65
|
28
|
42
|
13
|
30
|
31
|
27
|
25
|
26
|
23
|
36
|
77
|
45
|
35
|
35
|
15
|
15
|
14
|
20
|
9
|
5
|
|
| Cash Equivalents |
65
|
28
|
42
|
13
|
30
|
31
|
27
|
25
|
26
|
23
|
36
|
77
|
45
|
35
|
35
|
15
|
15
|
14
|
20
|
9
|
5
|
|
| Short-Term Investments |
0
|
0
|
1
|
30
|
30
|
25
|
11
|
11
|
11
|
15
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
62
|
67
|
52
|
56
|
58
|
58
|
56
|
42
|
29
|
34
|
30
|
23
|
56
|
34
|
34
|
17
|
13
|
14
|
13
|
8
|
38
|
|
| Accounts Receivables |
53
|
53
|
50
|
44
|
44
|
42
|
45
|
30
|
20
|
30
|
23
|
21
|
21
|
21
|
20
|
14
|
11
|
13
|
12
|
7
|
36
|
|
| Other Receivables |
9
|
13
|
2
|
12
|
14
|
15
|
11
|
11
|
9
|
4
|
7
|
2
|
35
|
13
|
15
|
4
|
2
|
1
|
1
|
2
|
2
|
|
| Inventory |
4
|
6
|
6
|
7
|
5
|
5
|
5
|
6
|
7
|
6
|
5
|
7
|
7
|
7
|
10
|
7
|
9
|
9
|
11
|
15
|
14
|
|
| Other Current Assets |
0
|
0
|
10
|
4
|
2
|
2
|
2
|
2
|
2
|
0
|
0
|
1
|
0
|
1
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
|
| Total Current Assets |
132
|
101
|
111
|
109
|
125
|
122
|
101
|
86
|
75
|
77
|
87
|
107
|
108
|
78
|
79
|
39
|
37
|
37
|
44
|
33
|
57
|
|
| PP&E Net |
29
|
37
|
40
|
33
|
31
|
29
|
27
|
24
|
17
|
15
|
14
|
13
|
11
|
37
|
41
|
54
|
52
|
53
|
51
|
50
|
57
|
|
| PP&E Gross |
29
|
37
|
40
|
33
|
31
|
29
|
27
|
24
|
17
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
6
|
8
|
11
|
15
|
19
|
23
|
26
|
29
|
37
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
8
|
7
|
6
|
5
|
5
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Goodwill |
3
|
3
|
3
|
3
|
3
|
3
|
3
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
4
|
4
|
4
|
4
|
3
|
3
|
3
|
3
|
3
|
3
|
8
|
8
|
0
|
1
|
1
|
1
|
1
|
1
|
|
| Other Assets |
3
|
3
|
3
|
3
|
3
|
3
|
3
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Total Assets |
163
N/A
|
141
-14%
|
153
+9%
|
149
-3%
|
163
+9%
|
165
+1%
|
143
-14%
|
122
-15%
|
102
-16%
|
102
0%
|
105
+3%
|
125
+19%
|
124
-1%
|
125
+1%
|
128
+3%
|
94
-27%
|
91
-3%
|
93
+2%
|
98
+6%
|
86
-12%
|
116
+35%
|
|
| Liabilities | ||||||||||||||||||||||
| Accounts Payable |
10
|
4
|
4
|
4
|
3
|
3
|
3
|
2
|
4
|
5
|
8
|
9
|
12
|
15
|
13
|
14
|
17
|
15
|
24
|
15
|
38
|
|
| Accrued Liabilities |
3
|
3
|
3
|
3
|
4
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Short-Term Debt |
39
|
19
|
25
|
21
|
25
|
23
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
15
|
15
|
0
|
0
|
0
|
15
|
15
|
15
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
15
|
15
|
0
|
0
|
15
|
15
|
15
|
0
|
0
|
1
|
|
| Other Current Liabilities |
0
|
0
|
2
|
1
|
0
|
0
|
3
|
2
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
52
|
26
|
34
|
28
|
32
|
29
|
6
|
4
|
6
|
5
|
13
|
24
|
27
|
30
|
29
|
29
|
32
|
31
|
40
|
31
|
54
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
1
|
1
|
1
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Minority Interest |
6
|
6
|
7
|
8
|
9
|
10
|
9
|
7
|
4
|
5
|
4
|
5
|
4
|
5
|
9
|
2
|
2
|
3
|
3
|
3
|
0
|
|
| Total Liabilities |
58
N/A
|
32
-44%
|
41
+26%
|
35
-13%
|
41
+16%
|
39
-4%
|
16
-60%
|
11
-26%
|
11
-3%
|
11
-5%
|
18
+68%
|
29
+63%
|
32
+12%
|
36
+11%
|
38
+7%
|
32
-17%
|
35
+10%
|
35
+1%
|
44
+25%
|
35
-21%
|
54
+56%
|
|
| Equity | ||||||||||||||||||||||
| Common Stock |
38
|
38
|
77
|
77
|
77
|
77
|
77
|
77
|
77
|
77
|
77
|
84
|
84
|
84
|
84
|
84
|
84
|
84
|
84
|
86
|
88
|
|
| Retained Earnings |
28
|
31
|
35
|
36
|
45
|
49
|
50
|
33
|
13
|
14
|
10
|
12
|
8
|
5
|
7
|
22
|
27
|
26
|
30
|
35
|
27
|
|
| Additional Paid In Capital |
39
|
39
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
105
N/A
|
109
+3%
|
113
+4%
|
114
+1%
|
122
+7%
|
126
+3%
|
127
+1%
|
110
-13%
|
91
-18%
|
91
+1%
|
87
-4%
|
96
+10%
|
92
-5%
|
89
-3%
|
90
+1%
|
62
-31%
|
56
-9%
|
57
+2%
|
54
-6%
|
51
-5%
|
62
+21%
|
|
| Total Liabilities & Equity |
163
N/A
|
141
-14%
|
153
+9%
|
149
-3%
|
163
+9%
|
165
+1%
|
143
-14%
|
122
-15%
|
102
-16%
|
102
0%
|
105
+3%
|
125
+19%
|
124
-1%
|
125
+1%
|
128
+3%
|
94
-27%
|
91
-3%
|
93
+2%
|
98
+6%
|
86
-12%
|
116
+35%
|
|
| Shares Outstanding | ||||||||||||||||||||||
| Common Shares Outstanding |
20
|
20
|
20
|
20
|
20
|
20
|
20
|
20
|
20
|
20
|
20
|
23
|
23
|
23
|
23
|
23
|
23
|
23
|
23
|
28
|
32
|
|